Charmacy Pharmaceutical Co., Ltd.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE1000023D6
HKD
5.80
0.00 (0.00%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

High Debt company with Weak Long Term Fundamental Strength

  • Poor long term growth as Net Sales has grown by an annual rate of 2.53% and Operating profit at 12.79% over the last 5 years
  • High Debt Company with a Debt to Equity ratio (avg) at times
2

Negative results in Dec 24

3

With ROE of 8.78%, it has a Very Expensive valuation with a 0.96 Price to Book Value

4

Below par performance in long term as well as near term

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

HKD 787 Million ()

stock-summary
P/E

11.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

6.33%

stock-summary
Debt Equity

2.32

stock-summary
Return on Equity

8.05%

stock-summary
Price to Book

1.21

Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-12.91%
0%
-12.91%
6 Months
-0.68%
0%
-0.68%
1 Year
-24.18%
0%
-24.18%
2 Years
-48.58%
0%
-48.58%
3 Years
-19.78%
0%
-19.78%
4 Years
-3.33%
0%
-3.33%
5 Years
28.89%
0%
28.89%

Charmacy Pharmaceutical Co., Ltd. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
2.53%
EBIT Growth (5y)
12.79%
EBIT to Interest (avg)
2.11
Debt to EBITDA (avg)
8.12
Net Debt to Equity (avg)
2.02
Sales to Capital Employed (avg)
1.95
Tax Ratio
25.15%
Dividend Payout Ratio
91.41%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
6.12%
ROE (avg)
8.99%

Valuation key factors

Factor
Value
P/E Ratio
11
Industry P/E
Price to Book Value
0.96
EV to EBIT
13.37
EV to EBITDA
10.56
EV to Capital Employed
0.99
EV to Sales
0.41
PEG Ratio
6.97
Dividend Yield
7.91%
ROCE (Latest)
7.37%
ROE (Latest)
8.78%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
Bearish
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by Charmacy Pharmaceutical Co., Ltd."
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'22",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2022 is 6.18% vs 1.88% in Dec 2021",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2022 is 276.70% vs -38.82% in Dec 2021",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'22",
        "Dec'21",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "4,843.60",
          "val2": "4,561.70",
          "chgp": "6.18%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "146.60",
          "val2": "130.00",
          "chgp": "12.77%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "47.70",
          "val2": "55.70",
          "chgp": "-14.36%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "105.10",
          "val2": "27.90",
          "chgp": "276.70%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "22.20%",
          "val2": "19.60%",
          "chgp": "0.26%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Annual Results Snapshot (Consolidated) - Dec'22stock-summary

Dec'22
Dec'21
Change(%)
Net Sales
4,843.60
4,561.70
6.18%
Operating Profit (PBDIT) excl Other Income
146.60
130.00
12.77%
Interest
47.70
55.70
-14.36%
Exceptional Items
0.00
0.00
Consolidate Net Profit
105.10
27.90
276.70%
Operating Profit Margin (Excl OI)
22.20%
19.60%
0.26%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2022 is 6.18% vs 1.88% in Dec 2021

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2022 is 276.70% vs -38.82% in Dec 2021

stock-summaryCompany CV
About Charmacy Pharmaceutical Co., Ltd. stock-summary
stock-summary
Charmacy Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available